- Agile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The company’s flagship product, Twirla, is already starting to display impressive growth trends.
- The market had a difficult time determining which direction it wants to take the share price, which has provided me an opportunity to add to my AGRX position.
- I will review the company's Q2 earnings and will highlight some key metrics for investors to follow as Twirla moves deeper into commercialization.
- I take a look at AGRX’s current valuation and will discuss how it influences the way I manage my position going forward.
For further details see:
Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy